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Levofloxacin-induced life-threatening  
hypoglycemia in a type 2 diabetic patient with 
ST-segment elevation myocardial infarction 
and community-acquired pneumonia
ABSTRACT 
Levofloxacin is a broad-spectrum, third-generation 
fluoroquinolone antibiotic used in the treatment of 
respiratory and urinary tract infections. Although it 
is usually well-tolerated, it may cause life-threatening 
adverse effects, including severe hypoglycemia. We 
present a case of levofloxacin-induced life-threatening 
hypoglycemia in a 87-year-old type 2 diabetic patient 
with ST-segment elevation myocardial infarction and 
community-acquired pneumonia. Hypoglycemia sec-
ondary to levofloxacin is a rare complication (< 0,1%), 
but can be more common among elderly patients, with 
type 2 diabetes (especially treated with hypoglycemic 
drugs) or renal dysfunction. Our patient was at high 
risk due to age, diabetes and chronic kidney disease 
(creatinine 149 µmol/L, estimated glomerular filtration 
rate 27 mL/min/1.73 m²). In the Naranjo probability 
scale, the patient scored 5 points, which indicates that 
hypoglycemia was a probable levofloxacin-related ad-
verse effect. In conclusion, we suggest that levofloxacin 
should be used with greater caution, particularly in 
patients at increased risk of hypoglycemia. (Clin Dia-
betol 2020; 9; 2: 141–143)
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Introduction
Levofloxacin is a broad-spectrum, third-generation 
fluoroquinolone antibiotic used in the treatment of 
respiratory and urinary tract infections [1–3]. Although 
it is usually well-tolerated, it may cause life-threatening 
adverse effects, including severe hypoglycemia [2–7].
Case presentation
An 87-year-old woman, a heavy smoker, with well-
-controlled type 2 diabetes (treated with glimepiride 
2 mg/d), chronic kidney disease, arterial hypertension, 
hyperlipidemia, hyperthyroidism (treated with me-
thimazole 20 mg/d), with frailty syndrome and chronic 
obstructive pulmonary disease, was admitted to the 
hospital due to acute anterior ST-segment elevation 
myocardial infarction (STEMI). On admission, the gly-
cated hemoglobin (HbA1c) level was 5.5% (37 mmol/ 
/mol), circulating thyrotropin (TSH) was 0.802 (normal: 
0.270–4.200) µIU/mL, free triiodothyronine (fT3) was 
4.34 (normal: 3.10–6.80) pmol/L and free thyroxine 
(fT4) was 15.95 (normal: 12.00–22.00) pmol/L. Serum 
creatinine concentration and estimated glomerular 
filtration rate (eGFR) were 168 µmol/L and 23 ml/ 
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/min/1.73 m², respectively. Fasting blood glucose levels 
were between 80 and 140 mg/dL and less than 180 mg/dL 
two hours after meal.
Urgent coronary angiography revealed subtotal 
proximal left anterior descending coronary artery 
stenosis and primary percutaneous angioplasty with 
drug-eluting stent implantation was immediately 
performed. On admission, the patient was diagnosed 
with community-acquired pneumonia and antibiotic 
treatment with ceftriaxone was initiated. On hospital 
day 6th, ceftriaxone was replaced with levofloxacin (500 
mg intravenously once daily) due to the lack of response 
to the treatment. After three doses of levofloxacin, on 
the 8th day of hospitalization, the patient developed 
symptoms of neuroglycopenia with decreased capillary 
blood glucose to 30 mg/dL. There was no deterioration 
in renal function (creatinine concentration and eGFR 
were 146 µmol/L and 25 mL/min/1.73 m², respectively). 
Within following 8 hours, seven ampoules of 10 ml 40% 
glucose injection and 1000 ml of 5% glucose infusion 
were administered. Then, due to persistent tendency 
to hypoglycemia, a continuous intravenous infusion 
of 40% glucose at 10–50 mL per hour was begun. 
Glimepiride was discontinued. After 5 days of successful 
antibiotic treatment, levofloxacin was switched from in-
travenous to oral administration and then discontinued. 
Gradual normalization of glycemia was observed. On 
the 11th hospital day  intravenous glucose infusion was 
stopped. No further episodes of hypoglycemia were 
observed during the next days of hospitalization. After 
recovery, the treatment of diabetes was changed. Based 
on the current  recommendation of Polish Diabetes As-
sociation and due to chronic kidney disease with final 
eGFR of 27 mL/min/1.73 m² and persistently increased 
risk of hypoglycemia the therapy with glimepiride was 
changed to linagliptin 5 mg/d.
Discussion
Levofloxacin is considered as a high effective and 
relatively safe fluoroquinolone antimicrobial used in the 
treatment of community-acquired pneumonia, com-
plicated urinary tract infections and acute bacterial si-
nusitis [1–3]. Hypoglycemia secondary to levofloxacin is 
a rare complication (< 0,1%), but can be more common 
among elderly patients, with type 2 diabetes (especially 
treated with hypoglycemic drugs) or renal dysfunction 
[2]. Our patient was at high risk due to age, diabetes 
and chronic kidney disease. In the Naranjo probability 
scale, the patient scored 5 points, which indicates that 
hypoglycemia was a probable levofloxacin-related ad-
verse effect (Tab. 1) [8]. 
The mechanisms underlying levofloxacin-induced 
hypoglycemia in diabetic patients are not fully under-
stood. There is increasing evidence that they are related 
to drug-drug interactions [9] or hyperinsulinemia [10]. It 
is postulated that there are two main pathomechanisms 
that may lead to fluoroquinolone-induced hypoglyce-
mia: pharmacokinetic and pharmacodynamic [9–12]. 
Table 1. Naranjo Adverse Drug Reaction (ADR) Probability Scale [2]
Question Yes No Do not 
know
Score in the  
presented patient
Are there previous conclusive reports on this reaction? +1 0 0 +1
Did the adverse event appear after the suspected drug was administered? +2 –1 0 +2
Did the adverse reaction improve when the drug was discontinued  
or a specific antagonist was administered?
+1 0 0 +1
Did the adverse reaction reappear when the drug was readministered? +2 –1 0 0
Are there alternative causes (other than the drug) that could on their own  
have caused the reaction?
–1 +2 0 0
Did the reaction reappear when a placebo was given? –1 +1 0 0
Was the drug detected in the blood (or other fluids) in concentrations known 
to be toxic?
+1 0 0 0
Was the reaction more severe when the dose was increased, or less severe 
when the dose was decreased?
+1 0 0 0
Did the patient have a similar reaction to the same or similar drugs in any  
previous exposure?
+1 0 0 0
Was the adverse event confirmed by any objective evidence? +1 0 0 +1
Total score: 5
Scoring: ≥ 9 = definite ADR; 5–8 = probable ADR; 1–4 = possible ADR; 0 = doubtful ADR
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The first one is associated with competitive metabolism 
of levofloxacin and sulfonylureas by cytochrome P450 
2C9 (CYP2C9) [9–12]. Pharmacodynamic theory is based 
on presumed fluoroquinolone-induced increase in insu-
lin release from pancreatic beta-cells [11]. Levofloxacin 
inhibits ATP-sensitive potassium channels causing de-
polarization of the beta-cell membrane, which results 
in opening voltage-dependent calcium channels and 
insulin secretion [11]. Other experimental studies using 
rat islet cells suggest that fluoroquinolones act not as 
initiators but rather as augmenters of stimulated insulin 
release from beta-cells [12]. Of the three fluoroqui-
nolones examined in the study with mouse pancreatic 
islets, levofloxacin appeared to be less likely to cause 
hypoglycemia than temafloxacin and gatifloxacin (both 
withdrawn from the market because of side effects, 
including hypoglycemia) [11]. However, in another 
study on rats, levofloxacin significantly affected glucose 
serum concentration in a dose-dependent manner [13]. 
Awareness about levofloxacin-induced hypogly-
cemia among physicians is relatively low. In a survey 
conducted in one of the university-affiliated teaching 
hospital, 80.4% of respondents were unaware about 
this adverse effect [4]. Importantly, this result may be 
underestimated due to a fatal case of levofloxacin-
-related hypoglycemia in this hospital, shortly before 
the questionnaire was conducted [4]. 
Clinical conditions to consider in the differential 
diagnosis of hypoglycemia in our patient include the 
following: chronic kidney disease, malnutrition, hy-
poglycemic effect of glimepiride, and less frequently 
— hyperthyroidism. 
The patient had a long history of chronic kidney 
disease, with no episodes of hypoglycemia in the past. 
We also found no deterioration in renal function dur-
ing hospitalization. Another cause of hypoglycemia 
might be malnutrition. However, during the patient’s 
stay in hospital, her nutritional status was good and 
she weighed approximately 60 kilograms. Glimepiride, 
which was used by the patient, may also induce hypo-
glycemia, however we have no reports of hypoglycemia 
episodes in the past medical history of the patient. In 
addition, despite the use of glimepiride during hos-
pitalization, blood glucose levels were normal until 
levofloxacin was included. Finally, hypoglycemia may 
have been a rare but possible complication of hyper-
thyroidism. It is well known that increased thyroid 
hormone levels are conducive to carbohydrate metabo-
lism disorders. Importantly, hyperthyroidism usually 
predisposes to hyperglycemia, due to intensified he-
patic gluconeogenesis, insulin resistance and increased 
glucose absorption from the gastrointestinal tract. An 
additional argument against hyperthyroidism-induced 
hypoglycemia is that the patient was in euthyroid state 
during hospitalization.
In conclusion, we suggest that levofloxacin should 
be used with greater caution, particularly in patients 
at increased risk of hypoglycemia.
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